New Directions in Immuno-oncology: Response and Resistance
Related
Watch on demand the live sessions held in February 2021
Description:
Immuno-oncology, the approach of harnessing the immune system to help fight cancer, has emerged in the last decade as one of the fastest-growing areas in cancer research with hundreds of potential treatments under investigation. As the field has accelerated, the issue of immuno-oncology resistance has arisen and is now a key area of high unmet medical need for cancer researchers to understand and address.
Watch this series of on-demand sessions dedicated to the latest breakthroughs in cell therapies, resistance to immunotherapies (tumor microenvironment and overcoming acquired resistance), and multiplex technologies. Gain insights into approaches impacting the field with talks from thought leaders across industry and academia.
Live sessions:
Cell therapies: Super charging the immune system
Webinar objectives
- Describe Hedgehog signaling in immune cells during the anti-tumor response
- Explain HLA-E and NKG2A as a novel immune checkpoint axis in bladder cancer
- Discuss the engineering of CAR T cells with improved persistence and resistance to the solid tumor microenvironment
Speakers
- Maike de la Roche, University of Cambridge, UK
- Hedgehog signaling in immune cells during the anti-tumor response
- Timestamp: 8:08 - 31:25
- Uriel Moreno, Johnson & Johnson, USA
- Plasticity of natural killer cells in the tumor microenvironment
- Timestamp: 32:35 - 1:00:30
- Deborah Moore-Lai, Abcam, USA
- Proteins and reagents for cell therapy research
- Timestamp: 1:01:20 - 1:19:10
- Amir Horowitz, Icahn School of Medicine at Mount Sinai, USA
Resistance to immunotherapies: Turning cold into hot - firing up the TME
Webinar objectives
- Discover how hypoxia drives tumor immune suppression and immunotherapy resistance
- Discuss overcoming resistance to STING-induced anti-tumour immunity
- Utilize in vivo labeling system to identify and isolate cells from the metastatic niche
Speakers
- Michael Curran, MD Anderson Cancer Center, USA
- Hypoxia drives tumor immune suppression and immunotherapy resistance
- Timestamp: 2:35 - 37:02
- Andrew Mellor, Newcastle University, UK
- Overcoming resistance to STING-induced anti-tumour immunity
- Timestamp: 38:06 - 1:06:45
- Luigi Ombrato, Barts Cancer Institute - Queen Mary University of London, UK
Resistance to immunotherapies: Mechanisms to overcome acquired resistance
Webinar objectives
- Discuss new directions for selective pathogenic roles for IDO1 in metastatic vasculogenesis and retinopathy
- Identify novel tools for integrated screens with single-cell readouts
- Review predictive biomarkers for immunotherapy response and resistance
Speakers
- George Prendergast, The Lankenau Institute for Medical Research, USA
- IDO/TDO targeting for cancer therapy: the path forward
- Timestamp: 7:20 - 34:12
- Mari Mino-Kenudson, Massachusetts General Hospital, USA
- Primary and acquired resistance to immunotherapies in lung cancer: Mechanisms and predictive biomarkers
- Timestamp: 35:25 - 59:15
- Benjamin Izar, Columbia University, USA
- Pooled screens with multi-modal single-cell profiling to define mechanisms of cancer immune evasion
- Timestamp: 1:00:27 - 1:28:17
- Rüdiger Greinert, Elbekliniken Stade/Buxtehude, Germany
Multiplex technologies to advance immuno-oncology and oncology discoveries
Webinar objectives
- Discuss key technology and technical hurdles for personalized medicine in immuno-oncology
- Review method for fluorescent multiplex immunostaining and related digital image analysis
- Discover how multiplexed imaging can be used to infer organization of immune cells in human tumors
Speakers
- Joe Yeong, A*STAR, Singapore
- The era beyond PD-L1: What can we do to help oncologists colleagues and patients further for personalized medicine?
- Timestamp: 8:20 - 38:57
- Leeat Keren, Weizmann Institute of Science, Israel
- Love thy neighbor – unraveling the tumor-immune microenvironment using multiplexed imaging
- Timestamp: 39:57 - 59:50
- Jacques Fieschi, HalioDx, France
- Bridging translation research to clinical application: Brightplex, a validated multiplex IHC technology to spatially explore the TME
- Timestamp: 1:00:37 - 1:25:23
- Adrien Guillot, Charité - Universitätsmedizin Berlin, Germany
- Multiplex immunohistochemistry on a single archival formalin-fixed paraffin-embedded tissue section
- Timestamp: 1:26:30 - 1:47:08
Contact
Have a question? Please contact the Abcam Events Team.